Profile
| Metric | Value |
|---|---|
| Full Name | Stoke Therapeutics, Inc. |
| Ticker | NASDAQ: STOK |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | stoketherapeutics.com |
| Employees | 128 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $29.25 | |
| Price, 1D Change | -0.58% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | 44.33 | |
| Beta | 0.91 | |
| Revenue | $37M | |
| Revenue, 1Y Change | +316.34% | |
| EPS | -$1.65 | |
| EPS, 1Y Change | +30.77% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.65 | |
| EPS Estimate | $0.06 | |
| EPS Est. Change | +103.41% | |
| Revenue | $36.56M | |
| Revenue Estimate | $188.75M | |
| Revenue Est. Change | +416.33% | |
| Current Price | $29.25 | |
| Price Target | - | $35.50 |
| Price Tgt. Change | - | +21.37% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.41 | -$2.38 | +1.25% | |
| -$2.02 | -$1.65 | +18.43% | |
| $0.06 | N/A | +103.41% | |
| -$3.16 | N/A | -91.50% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $9.62M | $8.78M | -8.73% | |
| $17.92M | $36.56M | +104.03% | |
| $188.75M | N/A | +416.33% | |
| $24.37M | N/A | -33.33% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +227.92% | |
| Price, 3Y | +200.00% | |
| Market Cap, 1Y | +246.64% | |
| Market Cap, 3Y | +334.47% | |
| Revenue, 1Y | +316.34% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | +30.77% | |
| EPS, 3Y | +29.46% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $29.25 | |
| SMA 200 | $19.30 | |
| SMA 200 vs Price | -34.01% | |
| SMA 50 | $30.09 | |
| SMA 50 vs Price | +2.88% | |
| Beta | 0.91 | |
| ATR | $2.40 | |
| 14-Day RSI | 41.50 | |
| 10-Day Volatility | 80.76% | |
| 1-Year Volatility | 72.41% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $36.56M | |
| EPS | -$1.65 | |
| Gross Profit | $32.11M | |
| Gross Margin | 87.85% | |
| Operating Profit | -$101.37M | |
| Operating Margin | -277.31% | |
| Net Income | -$88.98M | |
| Net Margin | -243.42% | |
| EBITDA | -$99.20M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.02 | |
| Current Ratio | 5.81 | |
| Quick Ratio | 5.81 | |
| - | ||
| F-Score | 8 | |
| Altman Z-Score | 20.79 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 44.33 | |
| PS Ratio | 8.12 | |
| PB Ratio | 5.42 | |
| EV/EBITDA | 45.41 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $229.02M | |
| Cash & Equivalents | $127.98M | |
| Total Assets | $271.56M | |
| Current Assets | $232.76M | |
| Total Liabilities | $42.53M | |
| Current Liabilities | $40.06M | |
| Total Debt | $4.77M | |
| Short Term Debt | $2.32M | |
| Accounts Payable | $2.50M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $137.93M | |
| Operating Expenses | $137.93M | |
| Cost Of Goods Sold | $4.44M | |
| SG&A | $48.79M | |
| D&A | $2.18M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$86.85M | |
| CFI | -$107.48M | |
| CFF | $131.09M | |
| Capex | $203.00K | |
| Free Cash Flow | -$87.05M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Chardan Capital | → | |
| Canaccord Genuity | → | |
| HC Wainwright & Co. | → | |
| Wedbush | → | |
| Canaccord Genuity | → | |
| BTIG | → | |
| JP Morgan | → | |
| BTIG | → | |
| Needham | → | |
| Wedbush | → |
Analyst sentiment
Institutional ownership
Screeners with STOK
Data Sources & References
- STOK Official Website www.stoketherapeutics.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1623526/000119312525264720/0001193125-25-264720-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1623526/000095017025041170/0000950170-25-041170-index.htm
- STOK Profile on Yahoo Finance finance.yahoo.com/quote/STOK
- STOK Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/stok
FAQ
What is the ticker symbol for Stoke Therapeutics, Inc.?
The ticker symbol for Stoke Therapeutics, Inc. is NASDAQ:STOK
Does Stoke Therapeutics, Inc. pay dividends?
No, Stoke Therapeutics, Inc. does not pay dividends
What sector is Stoke Therapeutics, Inc. in?
Stoke Therapeutics, Inc. is in the Healthcare sector
What industry is Stoke Therapeutics, Inc. in?
Stoke Therapeutics, Inc. is in the Biotechnology industry
What country is Stoke Therapeutics, Inc. based in?
Stoke Therapeutics, Inc. is headquartered in United States
When did Stoke Therapeutics, Inc. go public?
Stoke Therapeutics, Inc. initial public offering (IPO) was on June 19, 2019
Is Stoke Therapeutics, Inc. in the S&P 500?
No, Stoke Therapeutics, Inc. is not included in the S&P 500 index
Is Stoke Therapeutics, Inc. in the NASDAQ 100?
No, Stoke Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Stoke Therapeutics, Inc. in the Dow Jones?
No, Stoke Therapeutics, Inc. is not included in the Dow Jones index
When was Stoke Therapeutics, Inc. last earnings report?
Stoke Therapeutics, Inc.'s most recent earnings report was on November 4, 2025
When does Stoke Therapeutics, Inc. report earnings?
The next expected earnings date for Stoke Therapeutics, Inc. is March 24, 2026